Connective Tissue Disease Treatment Market Report 2025

The connective tissue disease treatment market size has grown strongly in recent years. It will grow from $23.08 billion in 2024 to $24.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the rising prevalence of autoimmune disorders, increased awareness of early diagnosis, improvements in healthcare infrastructure in developing regions, greater adoption of biologic therapies, and expanding insurance coverage for managing chronic diseases.

The connective tissue disease treatment market size is expected to see strong growth in the next few years. It will grow to $31.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth expected in the forecast period can be attributed to an expanding geriatric population, increased research and development investments by pharmaceutical companies, rising demand for personalized medicine, a growing pipeline of targeted therapies, and a focus on patient-centered care models. Key trends during this period include advancements in monoclonal antibody therapies, greater integration of telemedicine for disease monitoring, a shift toward biologics and biosimilars, development of multi-targeted drug regimens, and enhanced collaboration between academic and clinical research institutions.

The rising incidence of autoimmune diseases is expected to drive the growth of the connective tissue disease treatment market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks healthy tissues and organs. The increasing incidence is mainly caused by a combination of genetic susceptibility, which makes some individuals more vulnerable to immune system malfunctions, and environmental factors such as infections, diet, stress, and exposure to toxins that can trigger or worsen these conditions. Treatments for connective tissue diseases help manage autoimmune disorders by targeting the underlying immune dysfunction that leads to inflammation and tissue damage. This approach helps alleviate symptoms, slow disease progression, and improve the quality of life for patients with conditions like lupus, rheumatoid arthritis, and scleroderma. For example, in November 2024, Versorgungsatlas.de, a Germany-based healthcare data platform, reported that in 2022, 6,304,340 out of 73,241,305 insured individuals were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. Therefore, the rising incidence of autoimmune diseases is fueling the growth of the connective tissue disease treatment market.

Key companies in the connective tissue disease treatment market are focusing on clinical trials to develop innovative therapies such as allogeneic CAR-NK cell therapy, aiming to improve treatment effectiveness and address unmet needs in autoimmune diseases. Allogeneic CAR-NK cell therapy involves using natural killer (NK) cells from healthy donors that are genetically engineered with chimeric antigen receptors (CAR) to specifically target and destroy disease-causing cells. This therapy boosts the immune system's ability to eliminate harmful B-cells involved in autoimmune conditions and offers a potentially safer and more accessible alternative to conventional cell therapies. For instance, in July 2024, Nkarta Inc., a US-based clinical-stage biotech firm, initiated the Ntrust-1 clinical trial to assess NKX019, an investigational allogeneic CAR-NK cell therapy for lupus nephritis. The company also received FDA approval to start a separate trial (Ntrust-2) targeting systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis, aiming to improve safety, accessibility, and efficacy in autoimmune disease treatment by using genetically engineered NK cells that selectively target CD19-expressing B-cells.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition was intended to expand Amgen’s footprint in the rare and autoimmune disease market by incorporating Horizon Therapeutics’ portfolio of innovative and rapidly growing biologic therapies, including Tepezza, Krystexxa, and Uplizna. The deal strengthens Amgen’s pipeline, diversifies its revenue streams, and enhances its leadership position in specialty therapeutics. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company specializing in treatments for Sjögren’s syndrome and rheumatoid arthritis.

Major players in the connective tissue disease treatment market are Pfizer Inc., F. Hoffmann‑La Roche AG, AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) PLC, Eli Lilly and Company, Amgen Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Hikma Pharmaceuticals PLC, Innovent Biologics Inc., RemeGen Co. Ltd, Kymera Therapeutics, Adicet Bio, Equillium Inc., and Stem Cell Care India.

North America was the largest region in the connective tissue disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in connective tissue disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the connective tissue disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The connective tissue disease treatment market includes revenues earned by entities by providing services such as medication administration, physical rehabilitation, patient education, genetic counselling, long-term disease monitoring, and laboratory testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The connective tissue disease treatment market also includes sales of monoclonal antibodies, biologic agents, and corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The connective tissue disease treatment market research report is one of a series of new reports that provides connective tissue disease treatment market statistics, including the connective tissue disease treatment industry global market size, regional shares, competitors with the connective tissue disease treatment market share, detailed connective tissue disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the connective tissue disease treatment industry. These connective tissue disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Connective tissue disease treatment involves managing a group of autoimmune or inflammatory disorders that impact connective tissues like joints, skin, muscles, and internal organs. The goal is to reduce inflammation, regulate immune system activity, alleviate symptoms such as pain and fatigue, and prevent disease progression and organ damage.

The primary drug classes for treating connective tissue diseases include anti-inflammatory drugs, immunosuppressants, biologics and targeted therapies, disease-modifying anti-rheumatic drugs (DMARDs), and others. Anti-inflammatory drugs help decrease inflammation, pain, and swelling by inhibiting the body’s inflammatory response and are widely used in managing these diseases. These medications are prescribed for various conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, dermatomyositis, mixed connective tissue disease (MCTD), polymyositis, Sjögren's syndrome, vasculitis, and antiphospholipid syndrome (APS). Administration routes include oral, injectable, and topical forms. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users in hospitals, clinics, and homecare settings.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.